Davis Polk advised the underwriters in connection with an initial public offering of 5,060,000 shares of common stock of KYTHERA Biopharmaceuticals, Inc. (including 660,000 shares in respect of the exercise in full of the underwriters’ option to purchase additional shares) at $16.00 per share for gross proceeds of approximately $80.1 million. J.P. Morgan Securities LLC and Goldman, Sachs & Co. acted as joint book-running managers, Leerink Swann LLC acted as lead co-manager and Lazard Capital Markets LLC acted as co-manager. KYTHERA’s common stock is traded on the Nasdaq Global Select Market under the symbol “KYTH.”

Based in Calabasas, California, KYTHERA is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market.

The Davis Polk corporate team included partner Alan F. Denenberg and associate Peter M. Lamb and law clerk Siyu Jiang. The tax team included partner Rachel D. Kleinberg and law clerk Catherine Paskoff Chang. Counsel Cynthia Akard provided employment advice. Counsel Marcie A. Goldstein provided FINRA advice. The intellectual property team included partner Frank J. Azzopardi and associate Daniel Ray. Elizabeth J. Gordon was the legal assistant for the transaction. Members of the Davis Polk team are based in the Menlo Park and New York offices.



Related Posts:

Leave a Reply